Gri Bio Inc (GRI)

$2.06 -0.08 (-3.74%)
Market Cap 7.00M
Revenue (ttm) 0.00
Net Income (ttm) -8.21M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 215,600
Avg Vol 190,916
Day's Range N/A - N/A
Shares Out 3.27M
Stochastic %K 56%
Beta -1.48
Analysts Sell
Price Target $22.50

Company Profile

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a no...

Industry: Biotechnology
Sector: Healthcare
Phone: 619 400 1170
Address:
2223 Avenida de la Playa, Suite 208, La Jolla, United States
elkhro
elkhro Dec. 6 at 8:38 AM
$GRI like your account
0 · Reply
dbfkek112
dbfkek112 Dec. 6 at 3:07 AM
$GRI If Cro is done with the work, there is a very high possibility that the announcement will be made next week
0 · Reply
dButterz
dButterz Dec. 6 at 2:14 AM
$GRI i want what all you foos are smoking on🤣🤣🤣
0 · Reply
commanche
commanche Dec. 6 at 1:18 AM
$GRI added today based on gut feeling. Foolish gambling intensifies
0 · Reply
Mahdinur
Mahdinur Dec. 5 at 11:07 PM
$TGL $SMX $GRI What do these have in common? Low float
1 · Reply
Mahdinur
Mahdinur Dec. 5 at 11:06 PM
$GRI the sign of confidence
0 · Reply
Peaceouty
Peaceouty Dec. 5 at 11:05 PM
$GRI Probably AI generated..
0 · Reply
dbfkek112
dbfkek112 Dec. 5 at 10:26 PM
$GRI Big Pharma will try to negotiate if Gri brings the top data
0 · Reply
elkhro
elkhro Dec. 5 at 10:04 PM
$GRI their latest posts on X has been primarily on ipf. I think if news were bad, they would tone it down. I think positive data and new partner are the upcoming PMs. Therefore this taking so long. That is what I genuinely believe. I've been here for two years now.
0 · Reply
Mahdinur
Mahdinur Dec. 5 at 9:02 PM
$GRI perfectly closed
0 · Reply
Latest News on GRI
GRI Bio Reports 6-Week Interim Lung Function Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

Sep 11, 2025, 8:45 AM EDT - 3 months ago

GRI Bio Reports 6-Week Interim Lung Function Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

GRI Bio to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Aug 14, 2025, 9:15 AM EDT - 4 months ago

GRI Bio to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

GRI Bio CEO, Marc Hertz, Participates in Virtual Investor “What This Means” Segment

Jul 31, 2025, 1:50 PM EDT - 4 months ago

GRI Bio CEO, Marc Hertz, Participates in Virtual Investor “What This Means” Segment

GRI Bio Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Jul 22, 2025, 8:45 AM EDT - 4 months ago

GRI Bio Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

GRI Bio Completes Enrollment in Phase 2a Study of GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)

Jul 1, 2025, 8:45 AM EDT - 5 months ago

GRI Bio Completes Enrollment in Phase 2a Study of GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)

GRI Bio's GRI-0621 Demonstrates Encouraging Safety Results at Planned Interim 6-Week Analysis in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

Jun 26, 2025, 8:00 AM EDT - 5 months ago

GRI Bio's GRI-0621 Demonstrates Encouraging Safety Results at Planned Interim 6-Week Analysis in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

GRI Bio to Participate in the Virtual Investor Closing Bell Series

May 21, 2025, 9:15 AM EDT - 7 months ago

GRI Bio to Participate in the Virtual Investor Closing Bell Series

GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase

May 16, 2025, 9:15 AM EDT - 7 months ago

GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase

GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025

May 15, 2025, 8:35 AM EDT - 7 months ago

GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025

GRI Bio's Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

May 8, 2025, 8:45 AM EDT - 7 months ago

GRI Bio's Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)

May 7, 2025, 9:15 AM EDT - 7 months ago

GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)

GRI Bio Announces Abstract Selected for Poster Discussion Session at the 2025 American Thoracic Society (ATS) International Conference

Apr 16, 2025, 8:35 AM EDT - 8 months ago

GRI Bio Announces Abstract Selected for Poster Discussion Session at the 2025 American Thoracic Society (ATS) International Conference

GRI Bio Announces Closing of $5.0 Million Public Offering

Apr 2, 2025, 4:05 PM EDT - 8 months ago

GRI Bio Announces Closing of $5.0 Million Public Offering

GRI Bio Announces Pricing of $5.0 Million Public Offering

Apr 1, 2025, 11:15 AM EDT - 8 months ago

GRI Bio Announces Pricing of $5.0 Million Public Offering

Why Is Nano Cap GRI Bio Stock Skyrocketing On Tuesday?

Apr 1, 2025, 11:07 AM EDT - 8 months ago

Why Is Nano Cap GRI Bio Stock Skyrocketing On Tuesday?

GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan

Mar 31, 2025, 8:00 AM EDT - 8 months ago

GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan

GRI Bio Participates in a Virtual Investor CEO Connect Segment

Mar 18, 2025, 9:05 AM EDT - 9 months ago

GRI Bio Participates in a Virtual Investor CEO Connect Segment

GRI Bio Reports Full Year 2024 Financial Results and Reiterates Expected Clinical Data Readouts in 2025 for Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)

Mar 17, 2025, 8:05 AM EDT - 9 months ago

GRI Bio Reports Full Year 2024 Financial Results and Reiterates Expected Clinical Data Readouts in 2025 for Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)

GRI Bio Regains Compliance with Nasdaq's Minimum Bid Price Rule

Mar 11, 2025, 8:35 AM EDT - 9 months ago

GRI Bio Regains Compliance with Nasdaq's Minimum Bid Price Rule

GRI Bio Announces Reverse Stock Split

Feb 19, 2025, 4:05 PM EST - 10 months ago

GRI Bio Announces Reverse Stock Split

GRI Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 19, 2025, 9:00 AM EST - 10 months ago

GRI Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary Compounds

Dec 23, 2024, 9:00 AM EST - 1 year ago

GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary Compounds

GRI Bio Showcases GRI-0621's Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF)

Nov 21, 2024, 8:45 AM EST - 1 year ago

GRI Bio Showcases GRI-0621's Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF)

GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis

Nov 14, 2024, 4:20 PM EST - 1 year ago

GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis

GRI Bio Raises a Total of $13.9 Million in Gross Proceeds Since the Beginning of 2024

Oct 24, 2024, 8:30 AM EDT - 1 year ago

GRI Bio Raises a Total of $13.9 Million in Gross Proceeds Since the Beginning of 2024

GRI Bio Announces Exercise of Warrants

Oct 21, 2024, 5:35 PM EDT - 1 year ago

GRI Bio Announces Exercise of Warrants

GRI Bio Presents Positive Preclinical Data Demonstrating GRI-0621's Ability to Inhibit Invariant Natural Killer T (iNKT) Cell Activity and Reduce Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)

Oct 16, 2024, 8:45 AM EDT - 1 year ago

GRI Bio Presents Positive Preclinical Data Demonstrating GRI-0621's Ability to Inhibit Invariant Natural Killer T (iNKT) Cell Activity and Reduce Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)

GRI Bio Granted Japan Patent for Proprietary Natural Killer T (NKT) Cell Modulators for Prevention and Treatment of Inflammatory Conditions

Sep 30, 2024, 8:30 AM EDT - 1 year ago

GRI Bio Granted Japan Patent for Proprietary Natural Killer T (NKT) Cell Modulators for Prevention and Treatment of Inflammatory Conditions

GRI Bio (NASDAQ: GRI) to Participate in a Virtual Investor CEO Connect Segment

Sep 25, 2024, 8:45 AM EDT - 1 year ago

GRI Bio (NASDAQ: GRI) to Participate in a Virtual Investor CEO Connect Segment

GRI Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 5, 2024, 8:45 AM EDT - 1 year ago

GRI Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

GRI Bio to Present at the 2024 European Respiratory Congress

Sep 4, 2024, 8:45 AM EDT - 1 year ago

GRI Bio to Present at the 2024 European Respiratory Congress

GRI Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 14, 2024, 8:05 AM EDT - 1 year ago

GRI Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update

GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Lunch Break Series

Jul 15, 2024, 9:05 AM EDT - 1 year ago

GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Lunch Break Series

GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment

Jul 11, 2024, 9:20 AM EDT - 1 year ago

GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment

GRI Bio Regains Compliance with Nasdaq

Jul 8, 2024, 9:05 AM EDT - 1 year ago

GRI Bio Regains Compliance with Nasdaq

GRI Bio Announces Publication of Positive Preclinical Data from Lead Program GRI-0621 in the American Journal of Respiratory and Critical Care Medicine

Jul 2, 2024, 9:05 AM EDT - 1 year ago

GRI Bio Announces Publication of Positive Preclinical Data from Lead Program GRI-0621 in the American Journal of Respiratory and Critical Care Medicine

GRI Bio to Present at the 8th Annual IPF Summit

Jul 1, 2024, 8:45 AM EDT - 1 year ago

GRI Bio to Present at the 8th Annual IPF Summit

GRI Bio Announces Closing of $4.0 Million Public Offering

Jun 28, 2024, 4:05 PM EDT - 1 year ago

GRI Bio Announces Closing of $4.0 Million Public Offering

GRI Bio Announces Korea Patent Granted for Proprietary Natural Killer T (NKT) Cell Modulators

Jun 27, 2024, 9:00 AM EDT - 1 year ago

GRI Bio Announces Korea Patent Granted for Proprietary Natural Killer T (NKT) Cell Modulators

GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment Highlighting Positive Preclinical Data from Idiopathic Pulmonary Fibrosis (IPF) and Systemic Lupus Erythematosus (SLE) Programs

May 22, 2024, 9:15 AM EDT - 1 year ago

GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment Highlighting Positive Preclinical Data from Idiopathic Pulmonary Fibrosis (IPF) and Systemic Lupus Erythematosus (SLE) Programs

GRI Bio Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (SLE)

May 21, 2024, 8:35 AM EDT - 1 year ago

GRI Bio Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (SLE)

GRI Bio Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)

May 20, 2024, 8:45 AM EDT - 1 year ago

GRI Bio Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)

GRI Bio to Present at Alliance Global Partner's 2024 Healthcare Company Showcase

May 14, 2024, 9:05 AM EDT - 1 year ago

GRI Bio to Present at Alliance Global Partner's 2024 Healthcare Company Showcase

GRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 13, 2024, 8:00 AM EDT - 1 year ago

GRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

GRI Bio Announces Abstracts Accepted for Presentation at the 14th International Congress on Autoimmunity

Apr 29, 2024, 8:45 AM EDT - 1 year ago

GRI Bio Announces Abstracts Accepted for Presentation at the 14th International Congress on Autoimmunity

GRI Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

Apr 25, 2024, 9:15 AM EDT - 1 year ago

GRI Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T (NKT) Cell Modulators with Issuance of Korea Patent

Apr 16, 2024, 8:35 AM EDT - 1 year ago

GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T (NKT) Cell Modulators with Issuance of Korea Patent

GRI Bio Announces Abstract Accepted for Poster Presentation at the 2024 American Thoracic Society International Conference

Apr 8, 2024, 8:35 AM EDT - 1 year ago

GRI Bio Announces Abstract Accepted for Poster Presentation at the 2024 American Thoracic Society International Conference

GRI Bio Reports Full Year 2023 Financial Results and Provides Corporate Update

Apr 1, 2024, 7:35 AM EDT - 1 year ago

GRI Bio Reports Full Year 2023 Financial Results and Provides Corporate Update

GRI Bio to Present at the MedInvest Biotech & Pharma Investor Conference

Mar 28, 2024, 9:00 AM EDT - 1 year ago

GRI Bio to Present at the MedInvest Biotech & Pharma Investor Conference

elkhro
elkhro Dec. 6 at 8:38 AM
$GRI like your account
0 · Reply
dbfkek112
dbfkek112 Dec. 6 at 3:07 AM
$GRI If Cro is done with the work, there is a very high possibility that the announcement will be made next week
0 · Reply
dButterz
dButterz Dec. 6 at 2:14 AM
$GRI i want what all you foos are smoking on🤣🤣🤣
0 · Reply
commanche
commanche Dec. 6 at 1:18 AM
$GRI added today based on gut feeling. Foolish gambling intensifies
0 · Reply
Mahdinur
Mahdinur Dec. 5 at 11:07 PM
$TGL $SMX $GRI What do these have in common? Low float
1 · Reply
Mahdinur
Mahdinur Dec. 5 at 11:06 PM
$GRI the sign of confidence
0 · Reply
Peaceouty
Peaceouty Dec. 5 at 11:05 PM
$GRI Probably AI generated..
0 · Reply
dbfkek112
dbfkek112 Dec. 5 at 10:26 PM
$GRI Big Pharma will try to negotiate if Gri brings the top data
0 · Reply
elkhro
elkhro Dec. 5 at 10:04 PM
$GRI their latest posts on X has been primarily on ipf. I think if news were bad, they would tone it down. I think positive data and new partner are the upcoming PMs. Therefore this taking so long. That is what I genuinely believe. I've been here for two years now.
0 · Reply
Mahdinur
Mahdinur Dec. 5 at 9:02 PM
$GRI perfectly closed
0 · Reply
NolAsrtormZ
NolAsrtormZ Dec. 5 at 7:37 PM
$GRI .... anyone see that $SMX pump??? Well $PTIX has similar share float with drug data coming out soon. Trades at $1.70
1 · Reply
dButterz
dButterz Dec. 5 at 5:50 PM
$GRI go on now get out there in hit them streets and start pumping🤓🤓🤓🤓
0 · Reply
jimmy18000
jimmy18000 Dec. 5 at 5:22 PM
@Macme $GRI $CAPR I don’t know them much as I know CAPR. But the value ALONE at this depressed price of 2pps is worth the risk. If CAPR with 45mil shares can do 5x on data release, A good data on $GRI with micro float of 2.5 million will sure be fireworks! Market CAP is also currently at 5million!
2 · Reply
jimmy18000
jimmy18000 Dec. 5 at 4:52 PM
$GRI they have no money and need to raise a few weeks ago. Wonder why they didn’t…oh wait ! They’re going to raise cash at a much higher price after the good trial data. Same thing with what $CAPR just did. All IMO.
1 · Reply
gravetrencher
gravetrencher Dec. 5 at 3:04 PM
$GRI I see the pumpers, I see the bears, I’m just sitting here… patiently, watching, waiting, wondering.
0 · Reply
dbfkek112
dbfkek112 Dec. 5 at 3:04 PM
$GRI a strong buying spree
0 · Reply
Mahdinur
Mahdinur Dec. 5 at 2:53 PM
$GURE halt up $GRI waking
0 · Reply
Mahdinur
Mahdinur Dec. 5 at 1:45 PM
$GRI They are scammers who try to exploit peples emotions.
0 · Reply
dbfkek112
dbfkek112 Dec. 5 at 1:41 PM
$GRI This guy comes here all day and whines
1 · Reply
Peaceouty
Peaceouty Dec. 5 at 1:29 PM
$GRI buyout is unlikely since there’s twice the outstanding shares in warrants at 3.50.
0 · Reply
dButterz
dButterz Dec. 5 at 1:05 PM
$GRI
0 · Reply
Mahdinur
Mahdinur Dec. 5 at 12:31 PM
$LRHC $GRI $ADTX $SMX @Peaceouty @SuperStoner You guys keeping notes?
0 · Reply